Search Medical Condition
Please enter condition
Please choose location from dropdown

Groningen, Netherlands Clinical Trials

A listing of Groningen, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (256) clinical trials

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that pembrolizumab in combination with CRT ...

Phase

0.0 miles

Learn More »

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies

This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously treated solid tumors or hematologic malignancies.

Phase

0.0 miles

Learn More »

Phantom Motor Execution Via MPR VR/AR and SG as a Treatment of PLP

Sixty-six subjects with upper or lower limb amputations are planned to take part in this study. Subjects will be assigned randomly to PME and PMI treatments (2:1 proportion). After treatment completion (15 sessions of 2 hours each) and follow-up period of six months, patients that received PMI will be given ...

Phase N/A

0.0 miles

Learn More »

PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.

Invasive aspergillosis (IA) is the most common mould infection in immunocompromised haematological patients. A relatively low mortality is observed when diagnosis is made early and treatment with voriconazole, the first choice of treatment, is initiated promptly. However, azole resistance in Aspergillus fumigatus is increasingly reported in Europe. Fungal susceptibility testing ...

Phase N/A

0.0 miles

Learn More »

The Drug Rediscovery Protocol (DRUP Trial)

Problem description: evidence is building that matching targeted agents to tumor characteristics can improve outcomes. Such reports have fueled interest among patients and physicians to use molecular testing for treatment planning when standard treatment options have been exhausted. When oncologists aim to provide such personalized treatment to their patients though, ...

Phase

0.0 miles

Learn More »

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Complement 5a and its receptor C5aR (CD88) are involved in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This is a randomized, double-blind, active-controlled Phase 3 study to evaluate the safety and efficacy of the orally-administered, selective C5aR inhibitor CCX168 (avacopan) in inducing and sustaining remission in patients with anti-neutrophil ...

Phase

0.0 miles

Learn More »

Vemurafenib Plus Cobimetinib in Metastatic Melanoma

Molecular targeted therapy with BRAF inhibitor vemurafenib is now currently used as first line treatment for patients with unresectable stage IIIc or metastatic melanoma harboring the BRAFV600 mutation, which is present in about 50% of melanoma patients. Despite the improvement in Progression Free Survival (PFS) en Overall Survival (OS) compared ...

Phase

0.0 miles

Learn More »

Evaluation of a Physical Activity Program in Overweight Breast Cancer Patients

Rationale Patients diagnosed with breast cancer generally have a fairly well prognosis with estimated average survival rates of 73% and five year survival rates of 89% in developed countries (1). However, women who are obese at the time of breast cancer diagnosis seem to be at risk for a worse ...

Phase N/A

0.0 miles

Learn More »

A Study of CriPec Docetaxel Given to Patients With Solid Tumours

The study is designed to explore the safety, tolerability, pharmacokinetics and pharmacodynamics of CriPec docetaxel and to identify the Maximum Tolerated Dose (MTD).

Phase

0.0 miles

Learn More »

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

The trial is an open label extension study. Eligible patients from the RPC01-3101 trial diagnosed with moderate to severe ulcerative colitis will be enrolled to receive study medication for up to 5 years or until marketed approval.

Phase

0.0 miles

Learn More »